ACR Appropriateness Criteria: nonsurgical treatment for non-small-cell lung cancer: good performance status/definitive intent.
The optimal strategy for the non-surgical definitive treatment of patients with good performance status non-small cell lung cancer (mostly with locally advanced disease) has dramatically evolved over time. This article presents evidence-based data to review this literature. Several decades ago, the standard treatment for most stage III inoperable NSCLC was definitive radiation therapy alone. Randomized trials have since shown superior results with sequential chemotherapy and radiation, and more recently with concurrent chemoradiation, the current standard of care. Studies suggest a limited role for induction or adjuvant systemic therapy in addition to concurrent chemoradiation. The role of altered radiation fractionation techniques, such as hyperfractionation for locally advanced disease or hypofractionation for early stage disease is also discussed. More recently, the application of more advanced radiation techniques has been explored, including intensity modulated radiation therapy (IMRT) and proton beam radiation. Finally, various case variants are presented as examples of state-of-the-art treatment approaches.
Gewanter
Richard M
RM
Rosenzweig
Kenneth E
KE
Chang
Joe Yujiao
JY
Decker
Roy
R
Dubey
Sarita
S
Kong
Feng-Ming
FM
Lally
Brian E
BE
Langer
Corey J
CJ
Lee
Hoon Ku
HK
Movsas
Benjamin
B
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D019983:Guideline Adherence; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D017410:Practice Guidelines as Topic; D011879:Radiotherapy Dosage; D015996:Survival Rate